-- TCエナジー(TRP.TO)は、第1四半期の比較可能な利益が前年同期比で増加したと、金曜日に発表した報告書で明らかにした。 比較可能な利益は10億3000万カナダドル(1株当たり0.99ドル)で、前年同期の9億8300万カナダドル(1株当たり0.95ドル)から増加した。この結果は、ファクトセットがまとめた非GAAPベースの1株当たり利益のコンセンサス予想である0.97ドルを上回った。 比較可能なEBITDAは30億9000万ドルで、前年同期の27億1000万ドルから増加した。 同社は、2026年の比較可能なEBITDAガイダンスを116億ドルから118億ドルに据え置いた。2026年の比較可能なEBITDAおよび比較可能なEPSは、TCエナジーの2025年年次報告書の内容と一致し、2025年よりも高くなると予想されている。 非支配持分調整前の設備投資額は60億ドルから65億ドル、純設備投資額は55億ドルから60億ドルとなる見込みです。 さらに、TC Energyは、コロンビア・ガス・システムの拡張計画であるアパラチア供給プロジェクトを承認しました。このプロジェクトは、新規天然ガス火力発電の拡大に対応するため、1日あたり最大8億立方フィートの供給能力を提供することを目的としています。 このプロジェクトは2030年に稼働開始予定で、費用は約15億ドルと見積もられています。 TC Energyの取締役会は、6月30日を期末とする四半期について、普通株式1株当たり0.8775ドル(年率換算で3.51ドル)の四半期配当を決定しました。配当金は、6月30日営業終了時点の株主名簿に記載されている株主に対し、7月31日に支払われます。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.